Overview

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

Details

Lead Sponsor:

Bayer

Treatments:

Niacinamide
Sorafenib